Trump Administration Reports Premium Cuts as Medicare Advantage Continues Strategic Retrenchment Across States

The Centers for Medicare and Medicaid Services announced weighted average Medicare Advantage premiums will fall over 16 percent in 2027, with prescription drug components declining 38 percent, though insurers are simultaneously reducing plan availability and benefits. Plan choices will decrease in 29 of 51 states, with significant losses in Florida, Ohio, and Illinois offset by modest gains in Tennessee, Missouri, and Arizona, while preliminary data suggests between 2.9 million and 4.6 million beneficiaries were disrupted by plan closures. The CMS also implemented new enrollment restrictions on dual eligible special needs plans beginning in 2027, requiring beneficiaries to coordinate with the same carrier's Medicaid offerings.

The announcement reflects a complex reality within Medicare Advantage markets. While premium reductions appear favorable on the surface, insurers are simultaneously narrowing their offerings by closing plans and restricting benefits. Geographic disparities are pronounced, with certain states experiencing significant contraction—Florida losing over 50 plans—while others gain modest coverage expansions. The scale of disruption remains contested, with estimates of affected beneficiaries ranging from 2.9 million to 4.6 million depending on measurement methodology.

New regulatory constraints are reshaping plan strategies, particularly around dual-eligible enrollment. CMS's requirement that dual-eligible beneficiaries eventually coordinate with aligned Medicare-Medicaid plans through the same carrier represents a structural shift. Some insurers are responding by developing alternative special needs plans not subject to these alignment rules, while a small number are testing enrollment caps to manage business sustainability.